secwatch.observer — SEC 8-K summary
======================================

Issuer:     Profound Medical Corp. (PROF)
CIK:        0001628808
Form:       8-K
Filed at:   2026-10-09T17:11:55+00:00
Accession:  0001171843-26-006559
Event type: other_material
Sentiment:  positive
Materiality: 0.35
Item codes: 7.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Profound Medical, Telix sign co-education deal pairing PSMA-PET imaging with TULSA-PRO therapy
--------------------------------------------------------------------------------

- Co-education agreement pairs Telix's PSMA-PET agents Gozellix and Illuccix with Profound's MRI-guided, incisionless TULSA-PRO platform in prostate care.
- Planned initiatives: medical society meetings, KOL programs, educational summits, speaker programs, webinars, clinical case studies and best-practice content.
- Profound is developing PSMA-PET-MR image fusion for a planned future Treatment Delivery Console software release; no financial terms were disclosed.
- CEO Arun Menawat cites increased access to urologists via Telix; Telix Precision Medicine CEO Kevin Richardson cites more personalized patient care.
- CTO Mathieu Burtnyk: ~85% of prostate cancers are multifocal while ~15% are unifocal; ~15-25% of patients are focal-ablation candidates.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1628808/000117184326006559/0001171843-26-006559-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1628808/000117184326006559/f8k_100926.htm
  HTML page:      https://secwatch.observer/filing/0001171843-26-006559

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer